Healio

EMA grants orphan drug designation to spinal and bulbar muscular atrophy drug

Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has granted orphan drug designation to a small molecule intended to treat spinal ...
Nasdaq

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...
The New England Journal of Medicine

Treatment of Myasthenia Gravis with Germine Diacetate

Because bulbar muscle function was severely impaired it was necessary to continue pyridostigmine for Case 1 until about ten hours before administration. In Case 2, pyridostigmine was continued until ...
Nasdaq

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...